Guizhou Sanli Pharmaceutical Co.,Ltd (SHA:603439)
China flag China · Delayed Price · Currency is CNY
11.55
-0.37 (-3.10%)
Sep 10, 2026, 1:15 PM CST

SHA:603439 Income Statement

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Revenue
1,5591,7022,1441,6341,201938.84
Other Revenue
0.860.860.550.510.330.13
1,5601,7032,1441,6351,201938.97
Revenue Growth
-18.99%-20.59%31.16%36.10%27.94%48.99%
Cost of Revenue
452.22519.33652.98437.99339.52277.07
Gross Profit
1,1081,1841,4911,197861.8661.89
Selling, General & Admin
928.8948.31,089879.21618.01492.75
Research & Development
17.7427.9146.530.6117.867.68
Other Operating Expenses
18.626.8117.3116.611.018.56
Operating Expenses
959.55997.451,163929.77657.18509.98
Operating Income
148.56186.06328.34267.22204.62151.92
Interest Expense
-11.07-11.07-14.61-4.13-5.24-8.34
Interest & Investment Income
4.323.965.860.1317.5625.81
Other Non Operating Income (Expenses)
-12.19-0.05-0.371.89-0.21-0.09
EBT Excluding Unusual Items
129.62178.89319.16325.1216.74169.29
Impairment of Goodwill
-121.98-121.98---0.08-
Gain (Loss) on Sale of Investments
-2.72-2.620.15--0.09-
Gain (Loss) on Sale of Assets
0.1-0.12-0.170.59-0.09-0.15
Asset Writedown
-1.05-0.03-0.57-0.05-0.1-0.01
Other Unusual Items
13.6213.626.478.386.187.51
Pretax Income
17.5867.77325.03334.02222.56176.65
Income Tax Expense
17.0319.6145.1939.1530.6228.05
Earnings From Continuing Operations
0.5548.15279.84294.87191.94148.6
Minority Interest in Earnings
-0.18-1.9-5.81-2.179.353.68
Net Income
0.3746.25274.03292.7201.28152.28
Net Income to Common
0.3746.25274.03292.7201.28152.28
Net Income Growth
-99.84%-83.12%-6.38%45.42%32.18%62.08%
Shares Outstanding (Basic)
419420409412411412
Shares Outstanding (Diluted)
419420409412411412
Shares Change
1.10%2.81%-0.79%0.36%-0.19%5.14%
EPS (Basic)
0.000.110.670.710.490.37
EPS (Diluted)
0.000.110.670.710.490.37
EPS Growth
-99.85%-83.58%-5.63%44.90%32.43%54.17%

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
229.55138.7461.87167.97173.38128.96
Free Cash Flow Per Share
0.550.330.150.410.420.31
Dividend Per Share
0.0600.0600.3400.2000.100-
Dividend Growth
-82.35%-82.35%70.00%100.00%-60.00%-
Gross Margin
71.02%69.50%69.55%73.21%71.74%70.49%
Operating Margin
9.52%10.93%15.31%16.34%17.03%16.18%
Profit Margin
0.02%2.72%12.78%17.90%16.75%16.22%
Free Cash Flow Margin
14.71%8.15%2.89%10.27%14.43%13.73%
EBITDA
217.42258.84403.16303.64220.44163.09
EBITDA Margin
13.93%15.20%18.80%18.57%18.35%17.37%
D&A For EBITDA
68.8672.7874.8236.4215.8211.17
EBIT
148.56186.06328.34267.22204.62151.92
EBIT Margin
9.52%10.93%15.31%16.34%17.03%16.18%
Effective Tax Rate
96.86%28.94%13.90%11.72%13.76%15.88%
Revenue as Reported
1,7031,7032,1441,6351,201938.97
Advertising Expenses
-0.211.471.782.290.01